抗PD-1治疗增加小鼠B16F10黑色素瘤模型中癌细胞的[18F]FDG摄取
在小鼠B16F10黑色素瘤模型中,抗PD-1治疗后第7天治疗组肿瘤平均[18F]FDG摄取显著高于非治疗组(8.06 ± 0.48 %IA/g vs 4.02 ± 1.03 %IA/g,P = 0.0074),而治疗前两组差异可忽略。流式细胞术显示免疫细胞浸润可忽略,抗PD-1治疗显著增加CD45-癌细胞中葡萄糖转运蛋白1和己糖激酶II表达,表明癌细胞糖代谢增强。
要点
- 抗PD-1治疗后第7天治疗组肿瘤[18F]FDG摄取显著高于非治疗组(P = 0.0074)。
- 治疗前两组肿瘤[18F]FDG摄取差异可忽略。
- 癌细胞GLUT1和己糖激酶II表达显著增加,免疫细胞浸润可忽略。
核心结论
- 本研究表明抗PD-1治疗增加癌细胞的葡萄糖代谢。
研究设计与样本
- 在B16F10黑色素瘤小鼠模型中,于治疗前和治疗开始后7天进行[18F]FDG-PET,计算每克组织注射活度百分比(%IA/g)。
- 随后进行流式细胞术评估免疫细胞群体和葡萄糖代谢。
主要发现
- 治疗前治疗组与非治疗组肿瘤间[18F]FDG摄取差异可忽略。
- 抗PD-1治疗后治疗组肿瘤平均[18F]FDG摄取为8.06 ± 0.48 %IA/g,显著高于非治疗组的4.02 ± 1.03 %IA/g(P = 0.0074)。
- 肿瘤免疫细胞群体评估显示治疗轻度富集CD8+ T细胞和CD4+ T细胞,但免疫细胞浸润可忽略,免疫细胞不负责[18F]FDG摄取增加。
- 抗PD-1治疗显著增加CD45-癌细胞中葡萄糖转运蛋白1(GLUT1)和己糖激酶II表达。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Programmed cell death 1 (PD-1) inhibitors act as immune checkpoint inhibitors and are more effective for improving survival time with less toxicity as compared with conventional chemotherapies. In anti PD-1 therapy, it is important to evaluate metabolism in the cancer microenvironment, as this helps to clarify the pathological conditions. Herein, we investigate the early effects of PD-1 therapy on 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) uptake in vivo, focusing on cell distribution and glycolysis in both cancer and immune cells. RESULTS: In a B16F10 melanoma model, [18F]FDG-positron emission tomography (PET) was performed before treatment and 7 days after the start of treatment. Values were calculated as the percentage-injected activity per gram of tissue (%IA/g). Flow-cytometry was then performed to assess immune cell populations and glucose metabolism. There was a negligible difference in [18F]FDG uptake between tumors in the treatment group and non-treatment group before the treatment. In contrast, mean [18F]FDG uptake in the treatment group tumors was significantly higher (8.06 ± 0.48 %IA/g; P = 0.0074) than that in the non-treatment group (4.02 ± 1.03 %IA/g) after anti PD-1 treatment. Assessment of tumor immune cell populations showed that treatment slightly enriched CD8+ T cells and CD4+ T cells; however, infiltration of immune cells was negligible, and thus, immune cells were not responsible for the increase in [18F]FDG uptake. On the other hand, anti PD-1 treatment significantly increased glucose transporter 1 (GLUT1) and hexokinase II expression in CD45- cancer cells, indicating that anti PD-1 treatment increased glucose metabolism in cancer cells. CONCLUSION: The present study shows that anti PD-1 therapy increases glucose metabolism in cancer cells.
引用
- Tomita M, Yasui H, Higashikawa K, et al. Anti PD-1 treatment increases [18F]FDG uptake by cancer cells in a mouse B16F10 melanoma model. EJNMMI Res. 2018. PMID: 30117062. doi:10.1186/s13550-018-0433-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。